the Flanders Institute for Biotechnology Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2017
NCT03270501
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Flanders Institute of Biotechnology | the Flanders Institute for Biotechnology

Active Ingredients

Drugs in Phase 4 Trials (1)

sargramostim (leukine) (1 trial)

Drugs in Phase 3 Trials (1)

golimumab (simponi) (1 trial)

Drugs in Other Trials (2)

autologous fecal microbiota (1 trial)

human fecal microbiota (Reybota) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Inflammation (Phase 3)

Respiratory Insufficiency (Phase 4)

Spondylarthritis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 4